Evidence map›Paper›PMID 41816582›Full record

ArticleJournal of gastrointestinal oncology2026

The

Ruibing Li, Qiang Tao, Xijie Chen, Chuanyuan Liu, Huanmiao Zhan, Chong Wang, Xinyou Wang, Yijia Lin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ruibing Li *Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Qiang Tao *Department of Hepatobiliary and Pancreatic Surgery, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.
Xijie Chen *Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Chuanyuan LiuDepartment of General Surgery, The Ganzhou People's Hospital, Ganzhou, China.
Huanmiao ZhanDepartment of Pathology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Chong WangDepartment of General Surgery, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Xinyou WangGuangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Yijia LinGuangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cuproptosis represents a promising therapeutic strategy for colorectal cancer (CRC), yet the epigenetic mechanisms governing cuproptosis sensitivity remain largely unexplored. Enhancer of zeste homolog 2 ( Methods: Using elesclomol-copper complex treatment, a cuproptosis model in HCT116 and RKO CRC cell lines was established. Results: The elesclomol-copper treatment induced dose-dependent cell death characterized by Conclusions: The

Indexed as

colorectal cancer (CRC)Cuproptosisenhancer of zeste homolog 2 (EZH2)macrophage recruitmentNEAT1

Identifiers

PMID41816582
PMCPMC12972034

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.